Schroth W, Buettner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson D, Madden SF, Sauer G, Fehm T, Wallwiener D, Fasching P, Muerdter T, Schwab M, Brauch H (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 26
Pages Range: 6523-6534
Journal Issue: 24
DOI: 10.1158/1078-0432.CCR-20-1923
Purpose: Patients with estrogen receptor- and/or progesterone receptor-positive, early breast cancer benefit from hormonal treatment, yet high global death burdens due to high prevalence and long-term recurrence risk call for biomarkers to guide additional treatment approaches.
APA:
Schroth, W., Buettner, F.A., Kandabarau, S., Hoppe, R., Fritz, P., Kumbrink, J.,... Brauch, H. (2020). Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. Clinical Cancer Research, 26(24), 6523-6534. https://doi.org/10.1158/1078-0432.CCR-20-1923
MLA:
Schroth, Werner, et al. "Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients." Clinical Cancer Research 26.24 (2020): 6523-6534.
BibTeX: Download